Mission Therapeutics Successfully Completes First Clinical Assessment for Lead DUB Program, MTX652
Safety, tolerability and pharmacokinetic endpoints successfully met Follow-on clinical trials to be initiated in 2023 Mission Therapeutics ("Mission"), a drug discovery and development company focused on protein homeostasis by selectively …